Neurotrope Inc. | Ownership
Companies that own Neurotrope Inc.
Peter B. Cannell & Co., Inc.
270,793
3.43%
0
0.09%
06/30/2018
The Vanguard Group, Inc.
212,626
2.7%
230
0%
06/30/2018
Tanaka Capital Management, Inc.
198,195
2.5%
21,455
4.17%
06/30/2018
Oaktop Capital Management II LP
116,845
1.48%
0
0.22%
06/30/2018
1919 Investment Counsel LLC
110,000
1.39%
0
0.02%
06/30/2018
Neville, Rodie & Shaw, Inc.
109,375
1.39%
109,375
0.1%
06/30/2018
Iroquois Capital Management LLC
95,931
1.22%
-184,493
3.35%
12/31/2017
Eagle Capital Management LLC
59,745
0.76%
0
0%
06/30/2018
First Republic Investment Management, Inc.
58,623
0.74%
-301
0%
06/30/2018
Dimensional Fund Advisors LP
40,484
0.51%
-4,693
0%
06/30/2018
| Address |
205 East 42nd Street
New York New York 10017
United States
|
|
Employees
|
- |
| Website |
http://www.neurotropebioscience.com |
| Updated |
07/08/2019 |
| Neurotrope, Inc. is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. It operates through the following geographical segments: US; European Union; Japan; and China and India. It focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. |
